Literature DB >> 17823223

Heparin induced thrombocytopenia: diagnosis and management update.

I Ahmed1, A Majeed, R Powell.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a potentially devastating immune mediated adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of heparin. Despite thrombocytopenia, bleeding is rare; rather, HIT is strongly associated with thromboembolic complications involving both the arterial and venous systems. A number of laboratory tests are available to confirm the diagnosis; however, when HIT is clinically suspected, treatment should not be withheld pending the result. Fortunately, therapeutic strategies have been refined, and new and effective therapeutic agents are available. Treatment options are focused on inhibiting thrombin formation or direct thrombin inhibition. Warfarin should not be used until the platelet count has recovered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823223      PMCID: PMC2600013          DOI: 10.1136/pgmj.2007.059188

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  47 in total

Review 1.  Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.

Authors:  K R Campbell; K W Mahaffey; B E Lewis; J I Weitz; S D Berkowitz; E M Ohman; R M Califf
Journal:  J Invasive Cardiol       Date:  2000-12       Impact factor: 2.022

2.  Evaluation of a pharmacy-based surveillance program for heparin-induced thrombocytopenia.

Authors:  A C Andreescu; C Possidente; M Hsieh; M Cushman
Journal:  Pharmacotherapy       Date:  2000-08       Impact factor: 4.705

Review 3.  Heparin-induced thrombocytopenia: an overview.

Authors:  J G Kelton
Journal:  Blood Rev       Date:  2002-03       Impact factor: 8.250

4.  Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin.

Authors:  T B Keng; B H Chong
Journal:  Br J Haematol       Date:  2001-08       Impact factor: 6.998

5.  Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.

Authors:  P Eichler; H J Friesen; N Lubenow; B Jaeger; A Greinacher
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

6.  Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy.

Authors:  Marian P LaMonte; Philip M Brown; Marcie J Hursting
Journal:  Crit Care Med       Date:  2004-04       Impact factor: 7.598

7.  Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.

Authors:  J G Kelton; J W Smith; T E Warkentin; C P Hayward; G A Denomme; P Horsewood
Journal:  Blood       Date:  1994-06-01       Impact factor: 22.113

8.  Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.

Authors:  Sandeep Kodityal; Amit H Manhas; Mark Udden; Lawrence Rice
Journal:  Eur J Haematol       Date:  2003-08       Impact factor: 2.997

9.  Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.

Authors:  I Fox; A Dawson; P Loynds; J Eisner; K Findlen; E Levin; D Hanson; T Mant; J Wagner; J Maraganore
Journal:  Thromb Haemost       Date:  1993-02-01       Impact factor: 5.249

Review 10.  Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

Authors:  Duane S Pinto; Robert T Sperling; Thomas M Tu; David J Cohen; Joseph P Carrozza
Journal:  Catheter Cardiovasc Interv       Date:  2003-01       Impact factor: 2.692

View more
  58 in total

Review 1.  Novel oral anticoagulants for heparin-induced thrombocytopenia.

Authors:  Jessica W Skelley; Jeffrey A Kyle; Rachel A Roberts
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

2.  Bivalirudin as an Alternative Anticoagulant for Cardiopulmonary Bypass During Adult Cardiac Surgery-A Change in Practice.

Authors:  Peter Gatt; Samuel Anthony Galea; Walter Busuttil; Charles Grima; Jeffrey Muscat; Yvette Farrugia
Journal:  J Extra Corpor Technol       Date:  2017-03

3.  Two cases of heparin-induced thrombocytopenia after off-pump coronary artery bypass surgery.

Authors:  Kaushalendra Rathore; Evan Boon; Alex Wilson; Mark Newman
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-01-15

4.  Delayed-onset heparin-induced skin necrosis: a rare complication of perioperative heparin therapy.

Authors:  Weh Kiat Gan
Journal:  BMJ Case Rep       Date:  2017-11-03

5.  Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia.

Authors:  Tiffany K Pon; Anjlee Mahajan; Aaron Rosenberg; Alpesh Amin; Digish Shah; Ian Jenkins; Vineet Gupta; Heather Hofmann; Anthony Bejjani; Richard White
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

6.  Necessity of heparin for maintaining peripheral venous catheters: A systematic review and meta-analysis.

Authors:  Tao You; Jianliang Jiang; Jianchang Chen; Weiting Xu; Li Xiang; Yang Jiao
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

7.  Warfarin-induced skin necrosis following heparin-induced thrombocytopenia.

Authors:  Bilal Fawaz; Nicole M Candelario; Nicole Rochet; Connie Tran; Cristina Brau
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-01

8.  Complete Penile Necrosis in a Patient With Heparin-induced Thrombocytopenia: A Case Report.

Authors:  Anne-Sophie Blais; Marie-Pier Deschênes Rompré; Louis Lacombe
Journal:  Urol Case Rep       Date:  2014-01-24

9.  A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.

Authors:  Karen M Curzio; A Cheng-Lai; V Kheyfets; M Sinnet; H H Billett
Journal:  J Thromb Thrombolysis       Date:  2008-09-25       Impact factor: 2.300

10.  [Heparin-induced thrombocytopenia and liver hemorrhage following polytrauma].

Authors:  E Liodakis; F Hildebrand; M Frink; P Mommsen; C Krettek; C Probst
Journal:  Chirurg       Date:  2009-09       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.